Patents Assigned to Cancer Research Technology Ltd.
  • Publication number: 20060235058
    Abstract: Compound of a compound of formula (1) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R1 R2 R3 are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor, or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.
    Type: Application
    Filed: June 24, 2004
    Publication date: October 19, 2006
    Applicants: Vernalis (Cambridge) Limited, Cancer Research Technology Ltd., The Institute of Cancer Research
    Inventors: Kwai Cheung, Brian Dymock, Edward McDonald, Martin Drysdale
  • Patent number: 7118890
    Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: October 10, 2006
    Assignees: Yale University, Imperial Cancer Research Technology, Ltd.
    Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
  • Patent number: 7060450
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: November 13, 2000
    Date of Patent: June 13, 2006
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.
    Inventors: Clifford Tabin, Valeria Marigo, Philip W. Ingham, Andrew P. McMahon
  • Patent number: 7037915
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: May 2, 2006
    Assignees: Astellas Pharma Inc., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Publication number: 20060029544
    Abstract: The present invention provides novel receptor-binding cyclic peptides that advantageously display high receptor binding affinity and selectively. More particularly, the present invention provides integrin-binding cyclic peptides containing an integrin-binding motif such as an RGD motif, an aromatic amino acid such as a tyrosine residue, and a lysine residue having a pi-pi stacking moiety conjugated to its ?-amino group. Methods for identifying receptor-binding cyclic peptides and for using the cyclic peptides of the present invention for imaging a tumor, organ, or tissue and for treating cancer, inflammatory diseases, and autoimmune diseases are also provided.
    Type: Application
    Filed: August 5, 2005
    Publication date: February 9, 2006
    Applicants: The Regents of the University of California Office of Technology Transfer, Cancer Research Technology Ltd., Enterprises of Kings College London Capital House
    Inventors: Julie Sutcliffe-Goulden, John Marshall, Mark Howard, Michael O'Doherty
  • Publication number: 20050222230
    Abstract: The present invention pertains to the use of certain 3,4-diarylpyrazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxy; ether; formyl; acyl; carboxy; ester, acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamido; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N</SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
    Type: Application
    Filed: December 19, 2002
    Publication date: October 6, 2005
    Applicants: VERNALIS (CAMBRIDGE) LIMITED, CANCER RESEARCH TECHNOLOGY LTD., THE INSTITUE OF CANCER RESEARCH
    Inventors: Martin Drysdale, Brian Dymock, Xavier Barril-Alonso, Paul Workman, Laurence Pearl, Chrisostomos Prodromou, Edward Macdonald
  • Publication number: 20050142640
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: February 11, 2005
    Publication date: June 30, 2005
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce Taylor-Papadimitriou, Lukas Heukamp, Rienk Offringa, Cornelis Melief, Bruce Acres, Mireille Thomas
  • Patent number: 6838457
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: January 4, 2005
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6783956
    Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: August 31, 2004
    Assignees: Yale University, Imperial Cancer Research Technology, Ltd.
    Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
  • Patent number: 6770641
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: August 3, 2004
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6703489
    Abstract: The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: March 9, 2004
    Assignees: Yale University, Imperial Cancer Research Technology, Ltd.
    Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Anna Mary Myat, Robert J. Fleming, Spyridon Artavanis-Tsakonas, Robert S. Mann, Grace E. Gray
  • Patent number: 6664075
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: December 16, 2003
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
  • Patent number: 6653320
    Abstract: The present invention relates to novel compounds having a phosphatidylinositol 3 kinase (PI3K) inhibiting activity which are useful as medicaments, more particularly as antitumor agent. Novel 3-(imidazo[1,2-a]pyridin-3-yl) derivatives or salts thereof exhibit an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity, and are thus useful as medicaments, especially as PI3K inhibitors and antitumor agents.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: November 25, 2003
    Assignees: Yamanouchi Pharmaceutical Co. Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Ken-Ichi Kawaguchi, Koyo Matsuda, Noriko Ishikawa, Tomonobu Koizumi, Mayumi Yamano, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6630148
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: October 7, 2003
    Assignees: Imperial Cancer Research Technology Ltd., President and Fellows of Harvard College
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
  • Patent number: 6610656
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: August 26, 2003
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
  • Patent number: 6608056
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: August 19, 2003
    Assignees: Yamanouchi Pharmaceutical Co., Ltd, Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6608053
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: August 19, 2003
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6576237
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vetebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: June 10, 2003
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
  • Patent number: 6403588
    Abstract: The present invention relates to novel compounds having a phosphatidylinositol 3 kinase (PI3K) inhibiting activity which are useful as medicaments, more particularly as antitumor agent. Novel 3-(imidazo[1,2-a]pyridin-3-yl) derivatives or salts thereof exhibit an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity, and are thus useful as medicaments, especially as PI3K inhibitors and antitumor agents.
    Type: Grant
    Filed: April 26, 2001
    Date of Patent: June 11, 2002
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology, Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Ken-Ichi Kawaguchi, Koyo Matsuda, Noriko Ishikawa, Tomonobu Koizumi, Mayumi Yamano, Minoru Okada, Mitsuaki Ohta
  • Patent number: 6384192
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: May 7, 2002
    Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin